References
- Iwatsuki Y., Kaku S., Sakai-Moritani Y., Taniuchi Y., Mano Y., Usui T., Iizumi Y. Antithrombotic effect of YM466, a synthesized factor Xa inhibitor, in arterio-venous shunt thrombosis model in squirrel monkeys. Jpn. J. Pharmacol 2002; 88(suppl 1)76
- Uekama K. Pharmaceutical applications of cyclodextrin complexations. Yakugaku Zasshi 1981; 101: 857–873
- Loftsson T., Brewster M. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996; 85: 1017–1025
- Ueda M. Medicine and Drug Journal 2000; 36: 2763–2771
- Brewster M.E., Simpkins J.W., Hora M.S., Stern W.C., Boder N. The potential use of cyclodextrins in parenteral formulations. J. Parenter. Sci. Technol. 1989; 43: 231–240
- Yoshida A., Arima H., Uekama K., Pitha J. Pharmaceutical evaluation of hydroxyalkyl ethers of beta-cyclodextrins. Int. J. Pham. 1988; 46: 217–222
- Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965; 4: 117–212
- Napaporn J., Thomas M., Svetic K., Shahrokh Z., Brazeau G. Assessment of the myotoxicity of pharmaceutical buffers using an in vitro muscle model: effect of pH, capacity, tonicity, and buffer type. Pharm. Develop. Technol. 2000; 5: 123–130